CC 11006

Drug Profile

CC 11006

Alternative Names: CC-11006

Latest Information Update: 03 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Celgene Corporation
  • Class Anti-inflammatories; Antineoplastics; Small molecules
  • Mechanism of Action Immunomodulators; Interleukin 1 beta inhibitors; Interleukin 10 stimulants; Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Amyotrophic lateral sclerosis; Inflammation; Myelodysplastic syndromes

Most Recent Events

  • 31 Oct 2006 Preclinical trials in Amyotrophic lateral sclerosis in USA (PO)
  • 31 Oct 2006 Data presented at the 36th Annual Meeting of the Society for Neuroscience (SfN-2006) have been added to the Neurological disorders pharmacodynamics section
  • 04 Feb 2005 Phase-I clinical trials in Inflammation in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top